Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Phase 2 Completed 16 enrolled Masonic Cancer Center, University of Minnesota

NaSingle-groupOpen-labelTreatment

Summary

In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect. The investigators have designed a novel lymphodepleting conditioning regimen followed by infusion of donor-derived natural killer (NK) cells and interleukin-2 (IL-2) for patients with refractory lymphoid malignancies.

Timeline

Start: 2010-08
Primary completion: 2015-09
Completion: 2016-07

Publications

Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother. 2018 Mar;67(3):483-494. doi: 10.1007/s00262-017-2100-1. Epub 2017 Dec 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Subject	Fludarabine	Small molecule	25 mg/m2	Intravenous
Subject	Methylprednisolone	Other / unclassified	1 mg/kg	Intravenous
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	TROCULEUCEL	Cell therapy	1.5e+07 cells/kg	Intravenous
Subject	TROCULEUCEL	Cell therapy	8e+07 cells/kg	Intravenous
Background	aldesleukin	Protein / enzyme biologic	5e+06 unknown	Subcutaneous
Background	aldesleukin	Protein / enzyme biologic	9e+06 iu	Subcutaneous

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Summary

Timeline

Publications

Drugs

Indications